SavedAdd your journal

Journals / Ankara Üniversitesi Veteriner Fakültesi Dergisi / 2018 / Cilt: 65 - Sayı: 3

The comparison of clinical and cardiopulmonary effects of xylazine, medetomidine and detomidine in dogs

Köpeklerde xylazine, medetomidine ve detomidine’nin klinik ve kardiopulmoner etkilerinin karşılaştırılması

Ali BELGE
Rahime YAYGINGÜL
Pages
313–322
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Decrease in the respiration rate was statistically significant (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study intended to evaluate the effects of α2-adrenoceptor agonists (xylazine, medetomidine and detomidine) on clinical status and cardiopulmonary system in dogs.
📊
Key Findings & Data:A total of 30 dogs were randomly assigned to 3 different groups.
💡
Conclusion & Impact:Decrease in the respiration rate was statistically significant (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This study intended to evaluate the effects of α2-adrenoceptor agonists (xylazine, medetomidine and detomidine) on clinical status and cardiopulmonary system in dogs. A total of 30 dogs were randomly assigned to 3 different groups. Following fasting period of 12 hours, xylazine (1 mg/kg IM), medetomidine (25 µ/kg IM) and detomidine (20 µg/kg IM) were administered to groups I, II and III, respectively. Body temperature, heart rates, and respiratory rates were recorded at predetermined times before and after injections. Serum electrolyte, biochemical parameters, blood gases were also evaluated in the blood samples before and after injection. ECG was recorded before, during and after sedation. Decrease in heart rate was found significant in all of the groups. Decrease in the respiration rate was statistically significant (P

Özet

Bu çalışmada, köpeklerde α2-adrenoreseptör agonistlerinin (xylazine, medetomidine ve detomidine) klinik ve kardiopulmoner sistem üzerindeki etkilerinin değerlendirilmesi amaçlandı. Toplam 30 adet köpek rastgele olarak 3 farklı gruba ayrıldı. 12 saatlik açlığı takiben I. gruptaki köpeklere xylazine (1 mg/kg İM), medetomidine (25 µg/kg İM), detomidine (20 µg/kg İM) dozunda uygulandı. Enjeksiyon öncesi ve sonrası belirli zaman beden ısısı, kalp atım ve solunum sayıları kaydedildi. Enjeksiyon öncesi ve sonrası alınan kan örneklerinde serum elektrolitleri, biyokimyasal parametreler ve kan gazları değerlendirildi. Sedasyon öncesi, sırası ve sonrası EKG kaydedildi. Kalp atım sayısındaki azalma bütün gruplarda anlamlı bulundu. Solunum sayısındaki azalma I. ve II. grupta anlamlı iken (P

🔖

Cite This Article

BELGE, A., YAYGINGÜL, R. (2022). The comparison of clinical and cardiopulmonary effects of xylazine, medetomidine and detomidine in dogs. Ankara Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 65 - Sayı: 3, 313–322. https://ajindex.com/articles/444558

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Yamashita K, Tsubakishita S, Futaoka S, et al. (2000): Cardiovascular effect of medetomidine, detomidine, and xylazine in horses. J Vet Medi Sci, 62, 1025-32.
  2. Virtanen R (1986): Pharmacology of detomidine and other α2- adrenoreceptor agonists in the brain. Acta Vet Scand, 82, 35-46.
  3. Ünsüren H, Kurtdede A, Şeker Y, et al. (1986): Clinical, biochemical and haematological finding in dogs given Xylazine hydrochloride. Vet J Ankara Univ, 33, 373–380.
  4. Ueyena Y, Waselau AC, Wiese AJ, et al. (2008): Anesthetic and cardipulmonary effect of intramuscular morphine, medetomidine, ketamine injection in dogs. Vet Anaesth Analg, 35, 480-487.
  5. Sinclair DM (2003): A review of the physiological effect of α2- agonists related to the clinical use of medetomidine in small animal practice. Can Vet J, 44, 885-897.
  6. Simon F, Romvary A, Mora S (1989) Clinical investigations of medetomidine in dog. Acta Vet Scand Suppl, 85, 161-165.
  7. Seeler DC, Dodman NH, NormanWM, et al. (1987): Intraoperative cardiac dysrhythmias and their treatment. Brit Vet J, 143, 97-111.
  8. Savole JM, Ruskoaho H, Puurunen J, et al. (1986): Evidence for medetomidine as a selective and potent agonist at alpha-2 adrenoceptors. J Auton Pharmacol, 5, 275-284.
  9. Sarchahi AA, Vesal N, Nikahval B, et al. (2009): Comparison of the effects of different doses of acepromazine- xylazine on the electrocardiogram in dogs. Iran J Vet Res, 10, 208-215.
  10. Saraçoğlu A (2008): Drug-related cardivascular disorders. Turkiye Klinikleri J Cardiovasc Sci, 20, 107-123.
  11. Pypendop BH, Verstegen JP (1998): Hemodynamic effects of medetomidine in the dog: A dose titration study. Vet Surg, 27, 612-622.
  12. Pişkin I, Şireli M, Sağmanlıgil V, et al. (1999): The effects of some anaesthetics on the electrocardiograms of guinea pigs. Turk J Vet Anim Sci, 23, 161-166.
  13. Paddleford RR, Harvey RC (1999): Alpha-2 agonists and antagonists. Vet Clin North Am Small Anim Pract, 29, 737- 745. Özaydın İ, Atalan G, Uzun M, et al. (2001): Assessment of anaesthetic properties and clinical, cardiovascular and respiratoric effects of medetomidine, propofol and ketamine combination in dogs. J Fac Vet Med Kafkas Univ, 7, 71-76.
  14. Mohammad FK, Zangana IK, Al-Kassim NA (1991): Clinical observations in Shami goat kids sedated with medetomidine. Small Rum Res, 5, 149–153.
  15. Maze M, Tranquilli W (1991): Alpha-2 adrenoceptor agonist: Defining the role in clinical anesthesia. Anesthesiology 74, 581–605.
  16. Lemke KA (2004): Perioperative use of selective alpha-2 agonists and antagonists in sma